These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19527926)

  • 1. Estimation of an optimal chemotherapy utilisation rate for colon cancer: an evidence-based benchmark for cancer care.
    Jacob S; Ng W; Asghari R; Delaney GP; Barton MB
    Eur J Cancer; 2009 Sep; 45(14):2503-9. PubMed ID: 19527926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of an optimal chemotherapy utilisation rate for breast cancer: setting an evidence-based benchmark for the best-quality cancer care.
    Ng W; Delaney GP; Jacob S; Barton MB
    Eur J Cancer; 2010 Mar; 46(4):703-12. PubMed ID: 20034784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
    Ng W; Jacob S; Delaney G; Barton M
    Eur J Cancer; 2009 Aug; 45(12):2150-9. PubMed ID: 19285857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in rectal cancer: variation in utilization and development of an evidence-based benchmark rate of optimal chemotherapy utilization.
    Jacob S; Ng W; Asghari R; Delaney GP; Barton MB
    Clin Colorectal Cancer; 2011 Jun; 10(2):102-7. PubMed ID: 21859561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of an optimal chemotherapy utilisation rate for primary malignant brain tumours: an evidence-based benchmark for cancer care.
    Jacob S; Ng W; Delaney GP; Barton MB
    Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):48-54. PubMed ID: 20951557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of an optimal chemotherapy utilisation rate for cancer: setting an evidence-based benchmark for quality cancer care.
    Jacob SA; Ng WL; Do V
    Clin Oncol (R Coll Radiol); 2015 Feb; 27(2):77-82. PubMed ID: 25455844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.
    Delaney G; Jacob S; Barton M
    Cancer; 2004 Aug; 101(4):682-92. PubMed ID: 15305397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of an optimal utilisation rate for palliative radiotherapy in newly diagnosed cancer patients.
    Jacob S; Wong K; Delaney GP; Adams P; Barton MB
    Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):56-64. PubMed ID: 19969443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines.
    Delaney G; Shafiq J; Chappell G; Barton M
    Cancer; 2008 May; 112(9):1912-22. PubMed ID: 18318431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva.
    Delaney G; Jacob S; Barton M
    Cancer; 2004 Aug; 101(4):671-81. PubMed ID: 15305396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence.
    Delaney G; Barton M; Jacob S
    Cancer; 2004 Aug; 101(4):657-70. PubMed ID: 15305395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of an optimal chemotherapy utilisation rate for lung cancer: an evidence-based benchmark for cancer care.
    Jacob S; Hovey E; Ng W; Vinod S; Delaney GP; Barton MB
    Lung Cancer; 2010 Sep; 69(3):307-14. PubMed ID: 20080315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma.
    Delaney G; Jacob S; Barton M
    Cancer; 2005 Jun; 103(11):2216-27. PubMed ID: 15856428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines.
    Delaney G; Jacob S; Barton M
    Cancer; 2006 Jan; 106(2):453-65. PubMed ID: 16355366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies.
    Delaney G; Jacob S; Barton M
    Cancer; 2005 Feb; 103(3):462-73. PubMed ID: 15612081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of multidisciplinary lung cancer practice.
    Conron M; Phuah S; Steinfort D; Dabscheck E; Wright G; Hart D
    Intern Med J; 2007 Jan; 37(1):18-25. PubMed ID: 17199840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence.
    Delaney G; Barton M; Jacob S
    Cancer; 2004 Mar; 100(6):1293-301. PubMed ID: 15022299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.
    Delaney G; Jacob S; Featherstone C; Barton M
    Cancer; 2005 Sep; 104(6):1129-37. PubMed ID: 16080176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy.
    Fong A; Shafiq J; Saunders C; Thompson A; Tyldesley S; Olivotto IA; Barton MB; Dewar JA; Jacob S; Ng W; Speers C; Delaney GP
    Breast; 2012 Aug; 21(4):562-9. PubMed ID: 22297168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of an evidence-based benchmark for the optimal endocrine therapy utilization rate in breast cancer.
    Fong A; Ng W; Barton MB; Delaney GP
    Breast; 2010 Oct; 19(5):345-9. PubMed ID: 20223666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.